$JNJ

$270.15▲ +0.3% YTD

6 SEC 13D/G filings tracked · Last updated Sep 23, 2026

Filing History

CP $270.15▲ +0.3%Sep 23, 2026 · ThinkSabio Blog

$JNJ - New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fi…

News

JNJ ▲ +0.4% - Johnson & Johnson

CP $266.71▲ +0.4%Sep 15, 2026 · ThinkSabio Blog

$JNJ - RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-re…

News

JNJ ▼ -0.1% - Johnson & Johnson

CP $266.20▲ -0.1%Sep 14, 2026 · ThinkSabio Blog

$JNJ - Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion…

News

JNJ ▼ -1.6% - Johnson & Johnson

CP $270.62▲ -1.6%Sep 8, 2026 · ThinkSabio Blog

$JNJ - Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026…

News

JNJ ▲ +1.4% - Johnson & Johnson

CP $275.21▲ +1.4%Sep 2, 2026 · ThinkSabio Blog

$JNJ - Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit…

News

JNJ ▼ -0.7% - Johnson & Johnson

CP $266.06▲ -0.7%Aug 31, 2026 · ThinkSabio Blog

$JNJ - Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results…